Pemvidutide vs Survodutide: GLP-1/Glucagon Dual Agonist Comparison for Metabolic Research
Pemvidutide and survodutide are both Phase 2/3 GLP-1/glucagon dual agonists: compare their 16.6% vs 15.6% weight-loss data, MASH trial results, and FDA status.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Pemvidutide and survodutide are two of the most closely watched investigational GLP-1/glucagon dual receptor agonists in obesity and MASH (metabolic dysfunction-associated steatohepatitis) research, and researchers comparing pipeline candidates increasingly ask how the two programs actually differ in mechanism, trial design, and reported outcomes. Both compounds activate the same two receptor targets, but they come from different sponsors, use different molecular scaffolds, and have generated distinct evidence bases across Phase 2 and Phase 3 studies.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: Pemvidutide (Altimmune) is a balanced 1:1 GLP-1/glucagon dual agonist with Phase 2b data showing 15.6% weight loss and MASH resolution in 52–58% of participants, while survodutide (Boehringer Ingelheim/Zealand Pharma) is a Phase 3 dual agonist that reported 16.6% mean weight reduction at 76 weeks in the SYNCHRONIZE-1 trial — the two compounds are mechanistically similar but differ in development stage, sponsor, and the specific trials supporting their evidence base.
TL;DR:
- Both pemvidutide and survodutide activate GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR) pathways, combining appetite suppression with hepatic fat oxidation.
- Pemvidutide has completed Phase 2b trials in both obesity (MOMENTUM) and MASH (IMPACT); survodutide has advanced further, with Phase 3 obesity data reported (SYNCHRONIZE-1).
- Survodutide reported 16.6% mean weight reduction at 76 weeks; pemvidutide reported 15.6% weight loss at 48 weeks without a dose-titration period.
- Both hold FDA regulatory designations relevant to MASH — pemvidutide has Breakthrough Therapy Designation; survodutide has Breakthrough and Fast Track designations plus EMA PRIME status.
- Neither compound is FDA-approved; both remain investigational and are categorized as "Under Review" in 503A compounding status trackers.
Pemvidutide: mechanism and evidence base
Pemvidutide (formerly ALT-801) is a 23-amino-acid unimolecular GLP-1/glucagon dual receptor agonist developed by Altimmune. Its defining structural feature is a proprietary EuPort glycolipid moiety that extends half-life enough to support once-weekly subcutaneous dosing without the multi-week dose-titration schedule typically required for GLP-1-dominant agents. The full compound profile, including molecular formula and CAS number, is available on the pemvidutide library page.
Mechanistically, pemvidutide activates GLP-1R and GCGR with balanced, roughly 1:1 potency. GLP-1R agonism suppresses appetite through hypothalamic satiety pathways, slows gastric emptying, and enhances glucose-dependent insulin secretion. GCGR agonism drives direct hepatic lipid oxidation, increases energy expenditure through thermogenesis, and promotes lipolysis independent of caloric restriction — a combination researchers have flagged as particularly relevant to MASH pathology, since the glucagon-receptor component targets liver fat directly rather than only through reduced intake.
In the Phase 2b IMPACT trial (PMID 41237796), 212 adults with biopsy-confirmed MASH and fibrosis stages F2/F3 received pemvidutide 1.2 mg, 1.8 mg, or placebo weekly for 24 weeks. MASH resolution without fibrosis worsening was achieved in 58% of the 1.2 mg group and 52% of the 1.8 mg group, versus 20% with placebo (p<0.0001); fibrosis improvement of at least one stage without MASH worsening occurred in 34.5% of the 1.8 mg group. In the separate Phase 2b MOMENTUM obesity trial, the 2.4 mg dose produced 15.6% mean weight loss at 48 weeks against 2.2% for placebo, along with a 78.6% reduction in liver fat at the high dose. The FDA granted pemvidutide Breakthrough Therapy Designation for MASH in January 2026, and a registrational Phase 3 program spanning both MASH and obesity indications is planned.
Survodutide: mechanism and evidence base
Survodutide (BI 456906) is a 29-amino-acid acylated peptide developed jointly by Boehringer Ingelheim and Zealand Pharma. It carries a C18 fatty acid half-life-extending moiety along with a non-coded amino acid substitution (Ac4c) at position 2 for proteolytic stability, plus C-terminal amidation. Full chemistry and regulatory data are on the survodutide library page.
Like pemvidutide, survodutide simultaneously activates GLP-1R and GCGR. The GLP-1R component suppresses appetite and enhances glucose-dependent insulin secretion, while GCGR activation drives thermogenesis, hepatic fatty acid oxidation, and direct lipolysis. Altimmune and Boehringer Ingelheim/Zealand Pharma describe near-identical receptor-level rationale for the dual-agonist approach, though the two molecules differ in scaffold and half-life-extension chemistry.
Survodutide's most advanced published dataset is the Phase 3 SYNCHRONIZE-1 trial (PMID 41187967), a 76-week, multinational, randomized, double-blind, placebo-controlled study in adults with obesity or overweight plus comorbidities, without type 2 diabetes. Survodutide produced 16.6% mean weight reduction versus 3.2% with placebo (p<0.0001), meeting both co-primary endpoints, with 85.1% of survodutide-treated participants achieving at least 5% body weight reduction. An earlier Phase 2 dose-finding trial reported weight reductions roughly five-fold greater than placebo at 46 weeks, with the 4.8 mg arm showing the most robust efficacy signal. Survodutide also holds FDA Breakthrough Therapy and Fast Track designations for non-cirrhotic MASH with stage 2–3 fibrosis, along with EMA PRIME designation — regulatory pathways comparable to the newer GLP-1/GIP triple agonists such as retatrutide.
Side-by-side comparison
| Attribute | Pemvidutide | Survodutide |
|---|---|---|
| Sponsor | Altimmune | Boehringer Ingelheim / Zealand Pharma |
| Mechanism | Balanced GLP-1R/GCGR dual agonist | GLP-1R/GCGR dual agonist |
| Half-life extension | EuPort glycolipid moiety | C18 fatty acid + Ac4c substitution |
| Route | Subcutaneous, once weekly | Subcutaneous, once weekly |
| Furthest reported obesity data | Phase 2b MOMENTUM: 15.6% at 48 weeks | Phase 3 SYNCHRONIZE-1: 16.6% at 76 weeks |
| MASH data | Phase 2b IMPACT: 52–58% resolution | MASH studies ongoing under Breakthrough/PRIME designations |
| FDA designations | Breakthrough Therapy (MASH, Jan 2026) | Breakthrough Therapy + Fast Track (MASH); EMA PRIME |
| Regulatory status | Investigational | Investigational |
| 503A compounding status | Under Review | Under Review |
Differential research applications
Because survodutide has already reported Phase 3 obesity data while pemvidutide's most advanced obesity readout remains Phase 2b, researchers tracking regulatory timelines toward potential approval may prioritize survodutide when the research question centers on late-stage efficacy and safety signals at scale. Conversely, pemvidutide's IMPACT trial is one of the more complete published MASH-specific datasets among GLP-1/glucagon dual agonists, which makes it a common reference point for research protocols focused on hepatic fibrosis and steatohepatitis endpoints specifically rather than weight loss alone.
Both compounds are frequently modeled against comparator classes such as GLP-1 monoagonists (for example semaglutide), GLP-1/GIP dual agonists (for example tirzepatide), and other GLP-1/glucagon entrants such as mazdutide, which has already progressed to regulatory approval in China. Researchers cross-referencing trial phase, enrollment status, and expected data readouts across this comparator set can track current recruitment and results using the site's trial tracker.
Regulatory and compounding status
Neither pemvidutide nor survodutide is FDA-approved as of this writing; both remain investigational compounds progressing through sponsor-run clinical trial programs rather than the 503A/503B pharmacy compounding pathway. Both carry an "Under Review" 503A compounding status designation in the site's compound registry, reflecting that neither has an established compounding history comparable to older research peptides. Survodutide's EMA PRIME designation signals expedited European regulatory engagement, while pemvidutide's January 2026 FDA Breakthrough Therapy Designation applies specifically to the MASH indication rather than obesity. Researchers should consult primary sponsor disclosures and ClinicalTrials.gov listings directly for the most current trial status, since designations and enrollment can change between data cutoffs.
Cited studies
- PMID 41237796 — "Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study." (The Lancet, 2026). https://doi.org/10.1016/S0140-6736(25)02114-2
- PMID 41187967 — "Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1)." (Diabetes, Obesity and Metabolism, 2026). https://doi.org/10.1111/dom.70196
Frequently asked questions
Q: What is the main difference between pemvidutide and survodutide?
A: Both are GLP-1/glucagon dual receptor agonists studied for obesity and MASH, but they come from different sponsors and molecular scaffolds — pemvidutide uses Altimmune's EuPort glycolipid half-life-extension chemistry, while survodutide uses a C18 fatty acid conjugate. Survodutide has reported Phase 3 obesity data (SYNCHRONIZE-1), while pemvidutide's most advanced obesity trial to date is Phase 2b (MOMENTUM).
Q: Which company developed survodutide?
A: Survodutide (BI 456906) was developed jointly by Boehringer Ingelheim and Zealand Pharma. It has progressed through Phase 3 trials for obesity, including the SYNCHRONIZE-1 study reported in 2026.
Q: Does pemvidutide have MASH clinical trial data?
A: Yes. The Phase 2b IMPACT trial evaluated pemvidutide in 212 adults with biopsy-confirmed MASH and reported MASH resolution without fibrosis worsening in 52–58% of pemvidutide recipients versus 20% with placebo, supporting its January 2026 FDA Breakthrough Therapy Designation for MASH.
Q: How much weight loss has survodutide shown in Phase 3 trials?
A: In the Phase 3 SYNCHRONIZE-1 trial, survodutide produced a mean body weight reduction of 16.6% at 76 weeks compared with 3.2% for placebo, with 85.1% of participants achieving at least 5% body weight reduction.
Q: Are pemvidutide and survodutide interchangeable in research protocols?
A: No. Although both target the same receptor pair, they are distinct molecules with different pharmacokinetic profiles, dosing histories, and evidence bases at different trial phases. Researchers should treat published data for each compound as specific to that molecule rather than assuming direct equivalence.
See also:
- Retatrutide vs Tirzepatide: Triple vs Dual Agonist Mechanism Comparison — compares a GLP-1/GIP/glucagon triple agonist against a GLP-1/GIP dual agonist, useful context for the broader incretin-pathway comparator landscape.
- Semaglutide vs Retatrutide: Mono- vs Triple-Agonist Mechanisms — contrasts a single-pathway GLP-1 agonist against a multi-receptor agonist.
- Maridebart Cafraglutide vs Retatrutide: Two Approaches to Triple-Pathway Weight Loss Research — another head-to-head comparison of investigational incretin-pathway compounds.
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.